Analysts See Upside Potential in Schrodinger’s Strategic Shift

Shares of the biotechnology software firm Schrodinger advanced notably during Thursday's trading session. This upward move was fueled by a reiterated bullish stance from KeyBanc Capital Markets, signaling growing confidence on Wall Street regarding the company's ongoing strategic pivot.

The optimism surrounding Schrodinger is not solely based on analyst sentiment; it is supported by concrete financial improvements and institutional investment. For the third quarter of 2025, the company reported a significant jump in revenue, which reached $54.32 million compared to $35.29 million in the prior-year period. Concurrently, its adjusted net loss was narrowed to $32.8 million from a loss of $38.14 million a year earlier.

This improved financial picture has attracted increased attention from major investors. American Century Companies Inc. bolstered its stake in Schrodinger by 8.4% during the second quarter, bringing its total holding to 1,086,551 shares. At recent prices, this position was valued at approximately $21.86 million.

Analyst Conviction and Price Targets

KeyBanc analyst Scott Schoenhaus reaffirmed his Overweight rating on the stock, maintaining a price target of $28.00. Based on a recent closing price of $18.32, this projection implies a potential upside of roughly 52%. The current consensus among market researchers sits at a "Moderate Buy" recommendation, with the average price target standing at $26.50.

Should investors sell immediately? Or is it worth buying Schrodinger?

The company, which commands a market capitalization of about $1.35 billion, is in a transitional phase. Its strategic focus is on enhancing monetization of its proprietary software platform while aggressively reducing operational costs. Some observers believe this consolidation effort may be contributing to a potential undervaluation of the equity.

Technical Challenges and Market Dynamics

Despite the recent gains from lows around $16 to a close at $18.32, the technical outlook remains complex. The share price continues to trade below its key 50-day and 200-day moving averages, suggesting the medium-term downward trend has not yet been decisively reversed.

Future price action is expected to hinge critically on Schrodinger's execution of its cost-reduction initiatives alongside sustained growth in its core software business. Adding a layer of potential volatility is a significant short interest of approximately 13.6%, which could amplify price movements in either direction.